Sign in

Trial result ·

A double-blind, randomized, multicenter, phase 2b study of the safety and efficacy of suvecaltamide in essential tremor.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This study tested a drug called suvecaltamide for essential tremor. People in it had moderate to severe tremor. It was a phase 2b trial run at many sites. People were split by chance into groups. One group took a placebo once a day. A placebo has no active drug in it. The others took 10 mg, 20 mg, or 30 mg of the drug each day. Neither people nor staff knew who got what. The study lasted 12 weeks.

What they found

The trial did not meet its main goal. This goal was a change in a tremor score at week 12. Scores tended to improve more with higher doses than with placebo. But these gains were not big enough to rule out chance. Another scale measured how severe the tremor was overall. More people improved on 30 mg than on placebo, but not clearly. On 30 mg, common side effects were dizziness, tingling, and poor sleep. Others were tiredness, sleepiness, and worse tremor.

What it means for patients

The authors say the drug did not clearly beat placebo. This was true for the main goal and the key second goal. So this trial did not show a clear benefit from the drug. Some side effects, such as dizziness, were seen with the drug.

Why it is not certain yet

The small gains seen may be due to chance alone. The study lasted 12 weeks, so longer effects are not known. The abstract does not give full results for all the other goals. It also does not say how long side effects lasted.

Source

A double-blind, randomized, multicenter, phase 2b study of the safety and efficacy of suvecaltamide in essential tremor.

PubMed · PMID 42167194

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Essential tremor publications